Patent intelligence · US
US 10772942
Lyophilized factor IX formulations
Lyophilized factor IX formulations
Patent details — US 10772942
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 15, 2020
- Expiration
- Sep 10, 2040
- Applicant
- BIOVERATIV THERAPEUTICS INC.
- Claims
- 10
- CPC classes
- A61K, A61K38/4846, A61K47/183, A61K47/22
Quick answer
US 10772942 (Lyophilized factor IX formulations) is held by BIOVERATIV THERAPEUTICS INC.. Status: granted. Granted Sep 15, 2020. Expires Sep 10, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOVERATIV THERAPEUTICS INC.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K38/4846, A61K47/183, A61K47/22, A61K47/26, A61K9/0019
More from BIOVERATIV THERAPEUTICS INC.
Related pharmaceutical patents in our USPTO index.
-
US 12403164
Lentiviral vector formulations
granted -
US 12403183
Factor VIII polypeptide formulations
granted -
US 12391750
Anti-C1S antibodies and methods of use thereof
granted -
US 12371747
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
granted -
US 12364774
Nucleic acid molecules and uses thereof for non-viral gene therapy
granted -
US 12268688
Compositions and methods of use for modified release minoxidil
granted -
US 12257288
Methods of inducing immune tolerance to clotting factors
granted -
US 12240917
Anti-complement C1s antibodies and uses thereof
granted
Frequently asked questions
What is US patent 10772942?
US 10772942 (Lyophilized factor IX formulations) is held by BIOVERATIV THERAPEUTICS INC.. Status: granted. Granted Sep 15, 2020. Expires Sep 10, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10772942?
BIOVERATIV THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 140 pharmaceutical patents for this assignee.
When does US 10772942 expire?
Our index shows an expiration date of Sep 10, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.